In a study sponsored by Eli Lilly, people treated with Zepbound on average lost 20 percent of their weight over 72 weeks. Those who used Wegovy simultaneously lost 14 percent.
The side effects of the two preparations were often digestive problems according to the test.
The information lowered Novo Nordisk's share by 1.8 on the Copenhagen Stock Exchange, while Eli Lilly's share rose by 2.0 percent in futures trading on Wall Street.
